| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1104496271 |
| P356 | DOI | 10.1007/S11882-018-0790-X |
| P932 | PMC publication ID | 5994214 |
| P698 | PubMed publication ID | 29886521 |
| P50 | author | Alexander Karaulov | Q4214390 |
| Leyla Namazova-Baranova | Q29359263 | ||
| Musa Khaitov | Q30345117 | ||
| P2093 | author name string | Rudolf Valenta | |
| Raffaela Campana | |||
| Victoria Garib | |||
| Mirela Curin | |||
| P2860 | cites work | Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. | Q55277398 |
| Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections | Q57266970 | ||
| Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives | Q57266980 | ||
| Non–IgE-mediated chronic allergic skin inflammation revealed with rBet v 1 fragments | Q57920411 | ||
| Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation | Q58490825 | ||
| Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies | Q60312277 | ||
| Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients. | Q64910571 | ||
| Abrogation of reaginic antibodies with modified allergens | Q67589527 | ||
| [Therapy of atopic dermatitis in children. Study on the use of a desensitizing preparation] | Q68997663 | ||
| [Comparative evaluation of the effectiveness of different methods of prophylactic treatment for children with bronchial asthma] | Q69383937 | ||
| Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization | Q71046576 | ||
| Treatment of cat allergy with T-cell reactive peptides | Q71906922 | ||
| Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects | Q71943164 | ||
| Complex histaglobin and allergoid therapy of seasonal allergic diseases of the upper respiratory tract | Q72699779 | ||
| Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen Bet v 1 | Q74394674 | ||
| The latex allergen Hev b 5 transcript is widely distributed after subcutaneous injection in BALB/c mice of its DNA vaccine | Q77398129 | ||
| Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation | Q78145327 | ||
| Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis | Q79189373 | ||
| Allergen-specific immunotherapy with recombinant grass pollen allergens | Q81207775 | ||
| A hypoallergenic hybrid molecule with increased immunogenicity consisting of derivatives of the major grass pollen allergens, Phl p 2 and Phl p 6 | Q81641549 | ||
| Side-effects of allergen-specific immunotherapy: a prospective multi-centre study | Q82654593 | ||
| Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity | Q83153056 | ||
| Studies on "allergoids" prepared from naturally occurring allergens. I. Assay of allergenicity and antigenicity of formalinized rye group I component | Q24545738 | ||
| Amino acid sequence of Fel dI, the major allergen of the domestic cat: protein sequence analysis and cDNA cloning. | Q24560053 | ||
| Preferential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization | Q24599495 | ||
| Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future | Q26768511 | ||
| Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients | Q27700098 | ||
| Immunological mechanisms of allergen-specific immunotherapy | Q28265326 | ||
| Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis | Q30234365 | ||
| Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes | Q30238498 | ||
| Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I | Q30454050 | ||
| Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody | Q31107578 | ||
| Genetically engineered and synthetic allergen derivatives: candidates for vaccination against type I allergy | Q33737248 | ||
| Long-term clinical efficacy of grass-pollen immunotherapy | Q33870492 | ||
| Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study | Q34005065 | ||
| A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype | Q34106036 | ||
| Tolerization of a type I allergic immune response through transplantation of genetically modified hematopoietic stem cells | Q34361879 | ||
| Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. | Q34415246 | ||
| Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. | Q34430399 | ||
| Oral immunotherapy induces IgG antibodies that act through FcγRIIb to suppress IgE-mediated hypersensitivity | Q34664144 | ||
| The future of antigen-specific immunotherapy of allergy | Q34716363 | ||
| Renaissance of the blocking antibody concept in type I allergy | Q35557996 | ||
| Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. | Q35566610 | ||
| Immunotherapy of allergic disease | Q35671703 | ||
| Hypoallergenic Der p 1/Der p 2 combination vaccines for immunotherapy of house dust mite allergy | Q36125658 | ||
| Carrier-bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen-induced basophil activation in allergic patients. | Q36125684 | ||
| SEROLOGICAL EVIDENCE OF IMMUNITY WITH COEXISTING SENSITIZATION IN A TYPE OF HUMAN ALLERGY (HAY FEVER). | Q36256769 | ||
| Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions | Q36367890 | ||
| Isolation of an immunodominant IgE hapten from an epitope expression cDNA library. Dissection of the allergic effector reaction. | Q36676514 | ||
| Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy | Q36798594 | ||
| Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial | Q36970017 | ||
| Detection of IgE Reactivity to a Handful of Allergen Molecules in Early Childhood Predicts Respiratory Allergy in Adolescence | Q47340806 | ||
| Recombinant allergen and peptide-based approaches for allergy prevention by oral tolerance. | Q47939182 | ||
| Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. | Q50501197 | ||
| Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. | Q50850165 | ||
| Generation and Evaluation of Prophylactic mRNA Vaccines Against Allergy. | Q51253941 | ||
| Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. | Q51813678 | ||
| Combination of passive and active immunization in honeybee venom immunotherapy. | Q52463282 | ||
| Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines. | Q52767099 | ||
| Oral gene delivery with chitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. | Q52844746 | ||
| Immunize and disappear-safety-optimized mRNA vaccination with a panel of 29 allergens. | Q53059448 | ||
| Establishment of recombinant major allergens Bet v 1 and Phl p 5a as Ph. Eur. reference standards and validation of ELISA methods for their measurement. Results from feasibility studies. | Q53117473 | ||
| Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy. | Q53581091 | ||
| Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. | Q53988360 | ||
| A hypoallergenic cat vaccine based on Fel d 1-derived peptides fused to hepatitis B PreS. | Q54365271 | ||
| Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy | Q37008459 | ||
| Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection | Q37309327 | ||
| Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy | Q37309704 | ||
| Vaccination with genetically engineered allergens prevents progression of allergic disease. | Q37569798 | ||
| From allergen genes to allergy vaccines | Q37700719 | ||
| Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens | Q37847222 | ||
| Cell-based therapy in allergy | Q37877641 | ||
| Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives | Q37958561 | ||
| Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. | Q38013789 | ||
| International consensus on allergy immunotherapy. | Q38544969 | ||
| Windows of opportunity for tolerance induction for allergy by studying the evolution of allergic sensitization in birth cohorts | Q38633435 | ||
| Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: A phase I study | Q38729999 | ||
| Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life | Q38802935 | ||
| Allergic Rhinitis: Mechanisms and Treatment | Q38809265 | ||
| Specific allergen immunotherapy for the treatment of atopic eczema: a Cochrane systematic review | Q38835526 | ||
| Early childhood IgE reactivity to pathogenesis-related class 10 proteins predicts allergic rhinitis in adolescence | Q39070333 | ||
| Recombinant allergy vaccines based on allergen-derived B cell epitopes. | Q39284149 | ||
| Rational design of hypoallergens applied to the major cat allergen Fel d 1. | Q39366990 | ||
| Effect of ragweed hyperimmune human gamma globulin on in vivo and in vitro parameters of ragweed sensitivity | Q39375831 | ||
| Effects of passive antibody in bee venom anaphylaxis | Q39475985 | ||
| Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy | Q39782156 | ||
| Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. | Q39796254 | ||
| Risk factors for fatal and nonfatal reactions to subcutaneous immunotherapy: National surveillance study on allergen immunotherapy (2008-2013). | Q39944021 | ||
| Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study | Q40190132 | ||
| Molecular spreading and predictive value of preclinical IgE response to Phleum pratense in children with hay fever | Q40279334 | ||
| Prediction of peanut allergy in adolescence by early childhood storage protein-specific IgE signatures: The BAMSE population-based birth cohort | Q40338480 | ||
| Immunotherapy with T‐cell‐reactive peptides derived from allergens | Q40392723 | ||
| Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). | Q40588482 | ||
| Studies on allergoids from naturally occurring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever | Q40849553 | ||
| Evolution pathways of IgE responses to grass and mite allergens throughout childhood | Q40951587 | ||
| Prophylaxis of summer hay-fever and asthma: a controlled trial comparing crude grass-pollen extracts with the isolated main protein component | Q41034495 | ||
| The safety and efficacy of ALLERVAX CAT in cat allergic patients | Q41708614 | ||
| Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity | Q41745934 | ||
| Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy | Q41895016 | ||
| Hypoallergenic derivatives of Fel d 1 obtained by rational reassembly for allergy vaccination and tolerance induction. | Q42143464 | ||
| Development of an Allergy Immunotherapy Leads to a New Type of Hepatitis B Vaccine | Q42387623 | ||
| Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial | Q42789553 | ||
| Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy | Q43603745 | ||
| Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. | Q43711891 | ||
| Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. | Q44574133 | ||
| Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. | Q45102968 | ||
| Allergen-specific immunoprophylaxis: toward secondary prevention of allergic rhinitis? | Q45263896 | ||
| The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines | Q46398168 | ||
| Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. | Q46720701 | ||
| Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important | Q46961929 | ||
| Characterization of a hypoallergenic recombinant Bet v 1 variant as a candidate for allergen-specific immunotherapy | Q46970160 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 7 | |
| P921 | main subject | allergen | Q186752 |
| immunotherapy | Q1427096 | ||
| allergen immunotherapy | Q1641412 | ||
| hypersensitivity | Q5958765 | ||
| P304 | page(s) | 39 | |
| P577 | publication date | 2018-06-09 | |
| P1433 | published in | Current Allergy and Asthma Reports | Q2246111 |
| P1476 | title | Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches. | |
| P478 | volume | 18 |
| Q92955945 | A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens |
| Q57297464 | Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? |
| Q97681208 | Der p 1-based immunotoxin as potential tool for the treatment of dust mite respiratory allergy |
| Q90182025 | Dynamics Rationalize Proteolytic Susceptibility of the Major Birch Pollen Allergen Bet v 1 |
| Q93010272 | Efficacy of acupuncture at three nasal acupoints plus acupoint application for perennial allergic rhinitis: A multicenter, randomized controlled trial protocol |
| Q90858056 | Expression and characterization of recombinant Par j 1 and Par j 2 resembling the allergenic epitopes of Parietaria judaica pollen |
| Q90423881 | Mechanisms of allergen-specific immunotherapy for allergic rhinitis and food allergies |
| Q58606564 | Neoepitopes: a new take on beta cell autoimmunity in type 1 diabetes |
| Q59802672 | Precision medicine allergy immunoassay methods for assessing immunoglobulin E sensitization to aeroallergen molecules |
| Q98177685 | Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? |
| Q91977713 | Recombinant allergens for immunotherapy: state of the art |
| Q58554575 | Virus-Like Particles as Carrier Systems to Enhance Immunomodulation in Allergen Immunotherapy |
Search more.